Article
A clinical trial in early axial spondyloarthritis (axSpA) demonstrated sustained inactive disease status in over 60% of patients.
All News
Dr. John Cush
Tweet
Treat to Target Outcomes in Early AxSpA
Dr. Antoni Chan discusses abstract OP0132 presented at Eular 2024 in Vienna, Austria.
https://t.co/1svlH2GW9W https://t.co/oT1ZOPdR8e
Dr. John Cush
Tweet
Does Telemonitoring in SpA Work?
Dr. Antoni Chan reports on abstract OP0120 from Eular 2024 in Vienna, Austria.
https://t.co/UUmnsAdx0t https://t.co/NE36OtKBwK
Dr. John Cush
Tweet
Do MRI changes at the Spine and SI Joints in Treatment of AxSpA Matter?
Dr. Eric Ruderman discusses abstracts OP0046 and POS0058 presented at Eular 2024 in Vienna, Austria.
https://t.co/hYy7Wg2GMJ https://t.co/GVjtf89c3t
Dr. John Cush
Tweet
Inflammatory bowel disease in spondyloarthritis - does it matter?
Do the clinical features of axSpA patients with and without IBD differ?
https://t.co/t0wJRXXH0a https://t.co/iZsiP1AgWh
Peter Nash
Tweet
Telespa - telemonitoring in AxSpA « minimal impact on disease control « never examine a patient again , never find any pathology outside of joints, remote SpAologists, no longer physicians - easy to train rheumatology nurses to do our jobs @RheumNow #EULAR2024
Peter Nash
Tweet
Telespa - telemonitoring in AxSpA « minimal impact on disease control « never examine a patient again , never find any pathology outside of joints, remote SpAologists, no longer physicians - easy to train rheumatology nurses to do our jobs @RheumNow #EULAR2025
Dr. Antoni Chan
Tweet
Four phenotypes of chronic back pain suspicious of axial spondyloarthritis (axSpA) in the SPACE cohort. These groups were: They were “axial”, “axSpA with peripheral signs”, “at risk” and “no SpA”. Over a 2 year follow up, Transitions between the four classes over two years were… https://t.co/lF1wtAo46Q https://t.co/BXj1nw0tto
Dr. Antoni Chan
Tweet
Work ability is impaired in the majority of axSpA patients as measured by the WAI score. 996 patients were included with a mean WAI score of 31.7. Overall, 28%/43% of patients were in poor/moderate work ability, were older, more often obese , had lower education level and… https://t.co/D7oFn31Of5 https://t.co/g79riND9AO
Dr. Antoni Chan
Tweet
Reassessment of the cut-off values for ASDAS disease activity states in a large, multinational cohort of axSpA patients resulted in cut-offs largely similar to the currently endorsed cut-offs of 1.3, 2.1 and 3.5. Cut-off values between ID and LDA and between LDA and HDA, however,… https://t.co/vECCsmTggW https://t.co/XU7BQBYBdQ
Dr. Antoni Chan
Tweet
New validated BASDAI cut offs. BASDAI values of <2, <4 and >6 are often applied as cut-offs between remission, low (LDA), high (HDA) and very high (VHDA) disease activity, respectively, although this remains unvalidated. The optimal BASDAI values against external criteria were… https://t.co/5cvWoddHaN https://t.co/oBwYmFsIga
Peter Nash
Tweet
EULAR Abstract Archive
POS0894 (2024)
SAFETY OF UPADACITINIB ACROSS RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS, AND AXIAL SPONDYLOARTHRITIS ENCOMPASSING 15,000 PATIENT-YEARS OF CLINICAL TRIAL DATA
Reassuring 15000 pt yrs f/u RA PsA AS https://t.co/XWnzuVMlbn @RheumNow #EULAR2024
Mrinalini Dey
Tweet
POS0509 looks at time to diagnosis and #comorbidity burden in #axSpa
Retrospective study in French THIN database
Diagnostic delay remains common
Increased number of MSK & non-MSK manifestations & #comorbidities over time vs 1st presentation of back pain
@RheumNow #EULAR2024
Dr. Antoni Chan
Tweet
From the Be-GIANT cohort, 44.3% of patients met the definition of early axSpA (<2 year symptom). The early axSpA group had younger age and lower frequency of radiographic sacroiliitis. Baseline characteristics and disease activity scores at baseline were similar. Physicians… https://t.co/6stDw8sHiI https://t.co/fjINAc4mw3
Peter Nash
Tweet
THE ASSOCIATION BETWEEN DEPRESSION AND BIOLOGIC PRESCRIBING IN AXIAL SPONDYLOARTHRITIS (axSpA): LESSONS FROM AN IRISH axSpA COHORT more likely to have peripheral arthritis enthesitis psoriasis - shoukd we be formally assessing eg Beck’s DI @RheumNow #EULAR2024
Peter Nash
Tweet
MINIMAL SPINAL RADIOGRAPHIC PROGRESSION in RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS OVER 2 YEARS OF BIMEKIZUMAB TREATMENT: RESULTS FROM A PHASE 3 OPEN-LABEL EXTENSION STUDY - 90% nonprogressers on Bime including how many would never have progressed ? @RheumNow #EULAR2024
Mrinalini Dey
Tweet
POS0231 Safety of JAKi vs TNFi or IL-17 inhibitors in #PsA & #SpA
Results from a large population-based study show reassuring data, with no increased risk of #CVD, #VTE or certain cancers compared to TNFi or IL-17i
@SteZhao @RheumNow #EULAR2024
Dr. John Cush
Tweet
Do we need more IL-17 and JAK Inhibitors in Spondyloarthritis?
Dr. Eric Ruderman shares his perspectives on the following abstracts being presented at #EULAR2024 in Vienna, Austria:
OP0195
LBA0005
POS0803
OP0138
https://t.co/MnefRxYqMh https://t.co/Mwq4s7eTKY
Prof. Denis Poddubnyy
Tweet
Setting a standard for imaging reporting in patients with suspected axial spondyloarthritis is an important part of our efforts toward improving the early and accurate diagnosis of SpA:
https://t.co/zYbcL1CaTP https://t.co/1jnBDBSDNv
Nouf Al hemmadi
Tweet
Recommendation for management of fatigue in people with rheumatic disease.
Considering fatigue as a surrogate for inflammation and changing medication accordingly is part of it.
I will also add yearly blood work including:
1- VitD
2-HBA1c and LDl
3-TsH. https://t.co/3QvPqMxZSN
